CLEVELAND CLINIC FLORIDA PHARMACY SERVICES NONPROFIT CORPORATION

Harrow relaunches Triesence, a preservative-free triamcinolone acetonide injectable suspension for vitrectomy and ocular inflammation unresponsive to topical corticosteroids. The relaunch addresses a 5-year FDA Drug Shortage List absence, providing safer, more effective treatment for eyecare professionals and patients.